MedTrace Logo

In-office Assessment of Voiding Function Following Botox Injection for Overactive Bladder

NCT04155593 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 135

Last updated 2020-09-02

No results posted yet for this study

Summary

The purpose of this study is to describe the rates of elevated post void residual (PVR) (defined as \>200mL) in Cincinnati Urogynecology Associates patients following Botox injection, as well as to document how many patients required treatment with clean intermittent self-catheterization (CISC).

Conditions

Sponsors & Collaborators

  • TriHealth Inc.

    lead OTHER

Principal Investigators

  • Rachel Pauls, MD · TriHealth - Cincinnati Urogynecology Associates

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-08
Primary Completion
2020-03-25
Completion
2020-07-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04155593 on ClinicalTrials.gov